Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. 2015

Yogesh Mawal, and Ian A Critchley, and Todd A Riccobene, and Angela K Talley
a 1 Forest Laboratories, Inc., a subsidiary of Allergan plc (formerly Actavis plc) , New Jersey, USA.

Treatment of complicated urinary tract infections and complicated intra-abdominal infections is increasingly difficult due to the rising prevalence of multidrug-resistant Gram-negative bacteria. Ceftazidime-avibactam is a combination of the established third-generation cephalosporin ceftazidime with avibactam, a novel non-β-lactam β-lactamase inhibitor, which restores the activity of ceftazidime against many β-lactamase-producing Gram-negative bacteria, including extended-spectrum β-lactamases and Klebsiella pneumoniae carbapenemases. Clinical and nonclinical studies supporting the safety and efficacy of ceftazidime-avibactam include microbiological surveillance studies of clinically relevant pathogens, in vivo animal models of infection, pharmacokinetic/pharmacodynamic target attainment analyses, Phase I clinical pharmacology studies, and Phase II/III studies in the treatment of complicated intra-abdominal infections and complicated urinary tract infections, including patients with ceftazidime-nonsusceptible Gram-negative infections.

UI MeSH Term Description Entries
D002442 Ceftazidime Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime Anhydrous,Ceftazidime Pentahydrate,Fortaz,Fortum,GR-20263,LY-139381,Pyridinium, 1-((7-(((2-amino-4-thiazolyl)((1-carboxy-1-methylethoxy)imino)acetyl)amino)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-, inner salt, pentahydrate, (6R-(6alpha,7beta(Z)))-,Tazidime,GR 20263,GR20263,LY 139381,LY139381
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006090 Gram-Negative Bacteria Bacteria which lose crystal violet stain but are stained pink when treated by Gram's method. Gram Negative Bacteria
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014552 Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA. Infection, Urinary Tract,Infections, Urinary Tract,Tract Infection, Urinary,Tract Infections, Urinary,Urinary Tract Infection
D016905 Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method. Bacterial Infections, Gram-Negative,Infections, Gram-Negative Bacterial,Bacterial Infection, Gram-Negative,Gram Negative Bacterial Infections,Gram-Negative Bacterial Infection,Infection, Gram-Negative Bacterial
D053961 Azabicyclo Compounds Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS. Azabicyclo(1.1.0)Butanes,Azabicyclo(2.2.2)Octanes,Azabicyclo(3.3.1)Nonanes,Azabicyclo(4.3.0)Nonanes,Azabicyclo(5.2.2)Undecanes
D059413 Intraabdominal Infections Infection within the PERITONEAL CAVITY. A frequent cause is an ANASTOMOTIC LEAK following surgery. Intra-Abdominal Infections,Infection, Intra-Abdominal,Infection, Intraabdominal,Infections, Intra-Abdominal,Infections, Intraabdominal,Intra Abdominal Infections,Intra-Abdominal Infection,Intraabdominal Infection
D024901 Drug Resistance, Multiple, Bacterial The ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Drug Resistance, Extensive, Bacterial,Drug Resistance, Extensively, Bacterial,Extensive Antibacterial Drug Resistance,Extensively Antibacterial Drug Resistance,Multidrug Resistance, Bacterial,Multiple Antibacterial Drug Resistance,Bacterial Multidrug Resistance,Bacterial Multidrug Resistances,Resistance, Bacterial Multidrug

Related Publications

Yogesh Mawal, and Ian A Critchley, and Todd A Riccobene, and Angela K Talley
August 2016, P & T : a peer-reviewed journal for formulary management,
Yogesh Mawal, and Ian A Critchley, and Todd A Riccobene, and Angela K Talley
December 2016, Expert opinion on pharmacotherapy,
Yogesh Mawal, and Ian A Critchley, and Todd A Riccobene, and Angela K Talley
January 2015, Expert opinion on investigational drugs,
Yogesh Mawal, and Ian A Critchley, and Todd A Riccobene, and Angela K Talley
December 2019, Antibiotics (Basel, Switzerland),
Yogesh Mawal, and Ian A Critchley, and Todd A Riccobene, and Angela K Talley
January 2016, Drug design, development and therapy,
Yogesh Mawal, and Ian A Critchley, and Todd A Riccobene, and Angela K Talley
January 2016, Therapeutics and clinical risk management,
Yogesh Mawal, and Ian A Critchley, and Todd A Riccobene, and Angela K Talley
April 2019, Antimicrobial agents and chemotherapy,
Yogesh Mawal, and Ian A Critchley, and Todd A Riccobene, and Angela K Talley
June 2017, Future microbiology,
Yogesh Mawal, and Ian A Critchley, and Todd A Riccobene, and Angela K Talley
January 2016, Expert review of anti-infective therapy,
Copied contents to your clipboard!